Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 18/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641924 | 1.00 | HDAC1 (0.53) | HDAC1HDAC3HDAC2HDAC8CYP2C9 | |
| SCHEMBL22252987 | 0.91 | HDAC1 (0.54) | HDAC1HDAC3HDAC2HDAC8CYP2C9 | |
| SCHEMBL22234955 | 0.91 | HDAC1 (0.51) | HDAC1HDAC3HDAC2HDAC8CYP2C9 | |
| SCHEMBL22234950 | 0.91 | HDAC1 (0.51) | HDAC1HDAC3HDAC2HDAC8CYP2C9 | |
| SCHEMBL22252988 | 0.90 | HDAC1 (0.51) | HDAC1HDAC3HDAC2HDAC8CYP2C9 | |
| SCHEMBL22234584 | 0.90 | HDAC1 (0.57) | HDAC1HDAC3HDAC2HDAC8CYP2C9 | |
| SCHEMBL29642020 | 0.88 | HDAC1 (0.53) | HDAC1HDAC3HDAC2HDAC8CYP2C9 | |
| SCHEMBL22253196 | 0.88 | HDAC1 (0.53) | HDAC1HDAC3HDAC2HDAC8CYP2C9 | |
| SCHEMBL24285795 | 0.87 | HDAC1 (0.51) | HDAC1HDAC3HDAC2HDAC8CYP2C9 | |
| SCHEMBL22234991 | 0.85 | HDAC1 (0.48) | HDAC1HDAC3HDAC2HDAC8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089585-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2020150091-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089585-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.